Context Therapeutics (CNTX) Net Income (2020 - 2026)
Context Therapeutics (CNTX) posted Net Income of -$18.3 million for Q1 2026, down 13.87% sequentially from -$16.1 million in Q4 2025, and down 300.22% YoY from $9.1 million in Q1 2025.
Context Therapeutics (CNTX) Net Income (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Net Income for 7 years, with the latest figure at -$18.3 million in Q1 2026.
- Quarterly Net Income fell 300.22% year-over-year to -$18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$53.7 million (up 3.96% YoY) and the FY2025 annual result came in at -$72.2 million, down 40.29% from the prior year.
- Net Income slipped to -$18.3 million in Q1 2026 per CNTX's latest filing, from -$16.1 million in the prior quarter.
- Over five years, Net Income peaked at -$3.4 million in Q1 2022 and troughed at -$28.1 million in Q4 2024.
- A 5-year average of -$10.7 million and a median of -$6.8 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income plunged 319.73% in 2022, then soared 45.29% in 2025.
- Over 5 years, Net Income stood at -$13.1 million in 2022, then tumbled by 80.04% to -$23.5 million in 2023, then retreated by 19.4% to -$28.1 million in 2024, then soared by 42.85% to -$16.1 million in 2025, then decreased by 13.87% to -$18.3 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$18.3 million, -$16.1 million, and -$10.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -14.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.55 Mn |
| Mar 31, 2026 | -18.29 Mn |
| Dec 31, 2025 | -16.06 Mn |
| Sep 30, 2025 | -10.49 Mn |
| Jun 30, 2025 | -8.86 Mn |
| Mar 31, 2025 | -4.57 Mn |
| Dec 31, 2024 | -28.11 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -4.06 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -23.54 Mn |
| Sep 30, 2023 | -6.79 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | -13.07 Mn |
| Sep 30, 2022 | -4.05 Mn |
| Jun 30, 2022 | -4.01 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -3.11 Mn |
| Sep 30, 2021 | -1.61 Mn |